Sugi Predict

Sugi Predict / Compounds / SCHEMBL1415071

SCHEMBL1415071

SCHEMBL1415071

O=C(CSc1nc2ccccc2[nH]1)N1CCCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 1.00
▸ SMN1; SMN2 Q16637 4/20 1.00
▸ NPC1 O15118 3/20 1.00
▸ ALDH1A1 P00352 9/20 0.74
▸ MAPK1 P28482 2/20 0.74
▸ TDP1 Q9NUW8 3/20 0.73
▸ HPGD P15428 4/20 0.72
▸ TSHR P16473 3/20 0.72
▸ HSD17B10 Q99714 2/20 0.72
▸ KMT2A Q03164 4/20 0.66
▸ MEN1 O00255 2/20 0.66
▸ GAA P10253 2/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.64
▸ L3MBTL1 Q9Y468 2/20 0.64
▸ RXFP1 Q9HBX9 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP2D6 P10635 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ KDM4E B2RXH2 1/20 0.63
▸ USP2 O75604 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1415226 1.00 RAB9A (1.00) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL1415002 0.99 RAB9A (0.97) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL24549816 0.89 RAB9A (0.80) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL1415033 0.88 RAB9A (0.78) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL24550552 0.88 RAB9A (0.78) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL24549823 0.88 RAB9A (0.78) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL1415022 0.85 ALDH1A1 (1.00) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL1415096 0.85 ALDH1A1 (0.84) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL2025094 0.85 ALDH1A1 (1.00) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1
SCHEMBL7963947 0.84 RAB9A (0.70) RAB9ASMN1; SMN2NPC1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150202195-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2015-07-23 — — US claimed
US-9029376-B2 Small molecule inhibitors for the treatment or prevention of dengue virus infection SIGA TECHNOLOGIES, INC. (US) 2015-05-12 — — US claimed
US-20110158940-A1 SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2011-06-30 — — US claimed
EP-2293671-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION Siga Technologies, Inc. (US) 2011-03-16 — — EP claimed
WO-2009149054-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2009-12-10 — — WO claimed
US-20150202195-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2015-07-23 — — US disclosed
US-20150202195-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2015-07-23 — — US disclosed
US-20150202195-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2015-07-23 — — US disclosed
US-9029376-B2 Small molecule inhibitors for the treatment or prevention of dengue virus infection SIGA TECHNOLOGIES, INC. (US) 2015-05-12 — — US disclosed
US-9029376-B2 Small molecule inhibitors for the treatment or prevention of dengue virus infection SIGA TECHNOLOGIES, INC. (US) 2015-05-12 — — US disclosed
US-9029376-B2 Small molecule inhibitors for the treatment or prevention of dengue virus infection SIGA TECHNOLOGIES, INC. (US) 2015-05-12 — — US disclosed
US-20110158940-A1 SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2011-06-30 — — US disclosed
US-20110158940-A1 SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2011-06-30 — — US disclosed
US-20110158940-A1 SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. 2011-06-30 — — US disclosed
EP-2293671-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION Siga Technologies, Inc. (US) 2011-03-16 — — EP disclosed
WO-2009149054-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2009-12-10 — — WO disclosed
WO-2009149054-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SIGA TECHNOLOGIES, INC. (US) 2009-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202195-A1 SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION SNRPE, EIF2AK2, HAVCR2 RAB9A 966/4885SMN1; SMN2 1051/4885NPC1 696/4885
US-20110158940-A1 SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION HAVCR2, HNRNPLL, SAMSN1 RAB9A 2107/4885SMN1; SMN2 1972/4885NPC1 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.